The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. CRISPR Therapeutics AG’s current trading price is -17.75% away from its 52-week high, while its distance from the 52-week low is 57.71%. The stock’s price range for this period has been between $37.55 and $72.00 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 3.37 million for the day, a number notably higher than the average daily volume of 1.39 million over the last three months.
CRISPR Therapeutics AG (CRSP) stock is currently valued at $59.22. During the last session, the stock experienced a remarkable rise, reaching $60.41 after opening at $58.06. The stock briefly dropped to $55.76 before ultimately closing at $56.23.
CRISPR Therapeutics AG experienced a rather shaky stock market performance. The highest value in the past year was recorded at $72.00 on 05/23/23 and the lowest value was $37.55 on 10/23/23.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
CRISPR Therapeutics AG (CRSP) has experienced a quarterly rise of 25.76% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 4.70B and boasts a workforce of 458 employees.
CRISPR Therapeutics AG: What Analysts Are Saying
As of right now, 16 analysts are rating CRISPR Therapeutics AG as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 11 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 2 analysts are rating the stock as SELL.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 49.89, with a change in price of +2.99. Similarly, CRISPR Therapeutics AG recorded 1,281,315 in trading volume during the last 100 days, posting a change of +5.32%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for CRSP stands at 0.14. Similarly, the long-term debt-to-equity ratio is also 0.13.
CRSP Stock Stochastic Average
CRISPR Therapeutics AG’s raw stochastic average for the past 50 days is presently 94.79%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 94.79%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 88.72% and 81.16%, respectively.
CRSP Stock Price Performance Analysis
The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. Until today this year the stock’s price performance recorded an increase of 45.68%. However, over the last six months, the performance has been stronger by -8.06%. The price of CRSP increased 35.64% over the last 30 days. And in the last five days, it has surged by 15.53%.